Pathological gambling in Parkinson’s disease: disease related or drug related?

References

• Potenza MN, Kosten TR, Rounsaville BJ. Pathological gambling. JAMA286, 141–144 (2001).
   PubMed Web of Science ®Google Scholar
• Single E. Estimating the costs of substance abuse: implications to the estimation of the costs and benefits of gambling. J. Gambl. Stud.19(2), 215–233 (2003).
   PubMedGoogle Scholar
• American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• WHO. WHO International Statistical Classification of Diseases and Related Health Problems (10th Revision) (2003).
   Google Scholar
• Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson’s disease. Neuron61(4), 502–510 (2009).
   PubMed Web of Science ®Google Scholar
• Lader M. Antiparkinsonian medication and pathological gambling. CNS Drugs22(5), 407–416 (2008).
   PubMedGoogle Scholar
• Voon V, Fernagut PO, Wickens J et al. Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet Neurol.8(12), 1140–1149 (2009).
   PubMed Web of Science ®Google Scholar
• Frank MJ, Seeberger LC, O’Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science306(5703), 1940–1943 (2004).
   PubMed Web of Science ®Google Scholar
• Bódi N, Kéri S, Nagy H et al. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson’s patients. Brain132(Pt 9), 2385–2395 (2009).
   PubMed Web of Science ®Google Scholar
• Cilia R, Siri C, Marotta G et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch. Neurol.65(12), 1604–1611 (2008).
   PubMed Web of Science ®Google Scholar
• Steeves TD, Miyasaki J, Zurowski M et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain132(Pt 5), 1376–1385 (2009).
   PubMed Web of Science ®Google Scholar
• Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf.32(6), 475–488 (2009).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch. Neurol.63(7), 969–973 (2006).
   PubMed Web of Science ®Google Scholar
• Voon V, Hassan K, Zurowski M et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology67(7), 1254–1257 (2006).
   PubMed Web of Science ®Google Scholar
• Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol.62(9), 1377–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Gallagher DA, O’Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov. Disord.22(12), 1757–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol.67(5), 589–595 (2010).
   PubMed Web of Science ®Google Scholar
• Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch. Neurol.63(2), 298 (2006).
   PubMedGoogle Scholar
• Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfà F. Prevalence of pathological gambling in patients with Parkinson’s disease. Mov. Disord.21, 2068–2072 (2006).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J. Neurol. Neurosurg. Psychiatry68(4), 423–428 (2000).
   PubMed Web of Science ®Google Scholar
• Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O’Sullivan JD. Impulse control disorders in patients with Parkinson’s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction106(2), 283–293 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen J, Magalon D, Boyer L, Simon N, Christophe L. Aripiprazole-induced pathological gambling: a report of 3 cases. Curr. Drug Saf.6(1), 51–53 (2011).
   PubMedGoogle Scholar
• Antonini A, Siri C, Santangelo G et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson’s disease. Mov. Disord.26(3), 464–468 (2011).
   PubMed Web of Science ®Google Scholar
• Barns Neurauter MP, Rickards H, Cavanna AE. The prevalence and clinical characteristics of pathological gambling in Parkinson’s disease: an evidence-based review. Funct. Neurol.25(1), 9–13 (2010).
   PubMedGoogle Scholar
• Edens EL, Rosenheck RA. Rates and correlates of pathological gambling among VA mental health service users. J. Gambl. Stud. DOI: 10.1007/s10899-011-9239-z (2011) (Epub ahead of print).
   Google Scholar
• Kennedy SH, Welsh BR, Fulton K et al. Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder. Can. J. Psychiatry55(9), 568–576 (2010).
   PubMed Web of Science ®Google Scholar
• Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, Antonini A. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov. Disord.23(3), 411–415 (2008).
   PubMed Web of Science ®Google Scholar
• Lorains FK, Cowlishaw S, Thomas SA. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction106(3), 490–498 (2011).
   PubMed Web of Science ®Google Scholar
• Voon V, Thomsen T, Miyasaki JM et al. Factors associated with dopaminergic medication-related pathological gambling in Parkinson disease. Arch. Neurol.64(2), 212–216 (2007).
   PubMed Web of Science ®Google Scholar
• Siri C, Cilia R, De Gaspari D et al. Cognitive status of patients with Parkinson’s disease and pathological gambling. J. Neurol.257(2), 247–252 (2010).
   PubMed Web of Science ®Google Scholar
• Ledgerwood DM, Orr ES, Kaploun KA et al. Executive function in pathological gamblers and healthy controls. J. Gambl. Stud. DOI: 10.1007/s10899-010-9237-6 (2011) (Epub ahead of print).
   Google Scholar
• Rissling I, Geller F, Bandmann O et al. Dopamine receptor gene polymorphisms in Parkinson’s disease patients reporting ‘sleep attacks’. Mov. Disord.19(11), 1279–1284 (2004)
   PubMed Web of Science ®Google Scholar
• Kaiser R, Hofer A, Grapengiesser A et al.L-DOPA-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology60(11), 1750–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee EK, Park SS et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov. Disord.24(12), 1803–1810 (2009).
   PubMed Web of Science ®Google Scholar
• Eisenegger C, Knoch D, Ebstein RP, Gianotti LR, Sándor PS, Fehr E. Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. Biol. Psychiatry67(8), 702–706 (2010).
   PubMed Web of Science ®Google Scholar
• Slutske WS, Zhu G, Meier MH, Martin NG. Genetic and environmental influences on disordered gambling in men and women. Arch. Gen. Psychiatry67(6), 624–630 (2010).
   PubMed Web of Science ®Google Scholar
• Marinelli M, White FJ. Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. J. Neurosci.20(23), 8876–8885 (2000).
   PubMed Web of Science ®Google Scholar
• Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry? Lancet Neurol.2(10), 595–604 (2003).
   PubMed Web of Science ®Google Scholar
• Basar K, Sesia T, Groenewegen H, Steinbusch HW, Visser-Vandewalle V, Temel Y. Nucleus accumbens and impulsivity. Prog. Neurobiol.92(4), 533–557 (2010).
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Yoshikawa E, Okada H et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson’s disease: compartment analysis for β-CFT binding with positron emission tomography. Ann. Neurol.45, 601–610 (1999).
   PubMedGoogle Scholar
• Schultz W, Dayan P, Read Montague P. A neural substrate of prediction and reward. Science275, 1593–1599 (1997).
   PubMed Web of Science ®Google Scholar
• Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch. Neurol.61(5), 641–644 (2004).
   PubMed Web of Science ®Google Scholar
• Künig G, Leenders KL, Martin-Sölch C, Missimer J, Magyar S, Schultz W. Reduced reward processing in the brains of Parkinsonian patients. Neuroreport11(17), 3681–3687 (2000).
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Avila A, Barbanoj M, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels. Brain119, 2121–2132 (1996).
   PubMed Web of Science ®Google Scholar
• Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci. Biobehav. Rev.30(1), 1–23 (2006).
   PubMed Web of Science ®Google Scholar
• Voon V, Pessiglione M, Brezing C et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron65(1), 135–142 (2010).
   PubMed Web of Science ®Google Scholar
• Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in dopamine genes influences responsivity of the human reward system. Proc. Natl Acad. Sci. USA106(2), 617–622 (2009).
   PubMed Web of Science ®Google Scholar
• Cilia R, Ko JH, Cho SS et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol. Dis.39(1), 98–104 (2010).
   PubMed Web of Science ®Google Scholar
• Antonelli F, Ray N, Strafella AP. Imaging cognitive and behavioral symptoms in Parkinson’s disease. Expert Rev Neurother.10(12), 1827–1838 (2010).
   PubMed Web of Science ®Google Scholar
• van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson’s disease?.Neuropsychopharmacology34(13), 2758–2766 (2009).
   PubMed Web of Science ®Google Scholar
• Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology68(4), 301–303 (2007).
   PubMed Web of Science ®Google Scholar
• Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov. Disord.22(4), 590–591 (2007).
   PubMed Web of Science ®Google Scholar
• Abler B, Hahlbrock R, Unrath A, Grön G, Kassubek J. At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain132(9), 2396–2402 (2009).
   PubMed Web of Science ®Google Scholar
• van Eimeren T, Pellecchia G, Cilia R et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology75(19), 1711–1716 (2010).
   PubMed Web of Science ®Google Scholar
• Cilia R, Cho SS, van Eimeren T et al. Pathological gambling in patients with Parkinson’s disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov. Disord.26(2), 225–233 (2011).
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Trojano L, Verde F, Rocco M, Grossi D, Barone P. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Mov. Disord.26(5), 830–836 (2011).
   PubMed Web of Science ®Google Scholar
• Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol.8(10), 929–937 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann. Neurol.68(3), 400–404 (2010).
   PubMed Web of Science ®Google Scholar